ライフサイエンスコーパス: epistaxis

1 ilate pretreatment (three haematuria and one epistaxis).

2 to the emergency department with intractable epistaxis.

3 d reduced duration and number of episodes of epistaxis.

4 in children, as in adults, were headache and epistaxis.

5 nts), gastrointestinal bleeding (1 patient), epistaxis (1 patient), and antibiotic-responsive febrile

6 davunetide group than in the placebo group (epistaxis 18 [12%] of 156 vs 13 [8%] of 156, rhinorrhoea

7 t (AE) (most commonly fatigue, headache, and epistaxis); 19% (n = 12) reported >/=1 serious AE; 10 (1

8 33 (25%) patients (70% gastrointestinal, 21% epistaxis, 3% genitourinary, and 6% intracranial).

9 intestinal (45% of events), wound (12%), and epistaxis (4%).

10 These three individuals had epistaxis and dermal lesions that were described as tela

11 Her mother was reported to have frequent epistaxis and similar skin lesions.

12 of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycaemia).

13 sorders presented with abdominal distension, epistaxis, and anemia (hemoglobin 8.2 g/dL).

14 d patients; postprocedural bleeding (in 3%); epistaxis associated with the use of fish-oil supplement

15 The frequency of epistaxis decreased from 30 to 15 episodes per month.

16 Mean monthly epistaxis duration for 3 consecutive months immediately

17 pared with a placebo, did not reduce monthly epistaxis duration in the 3 consecutive months immediate

18 Mean monthly epistaxis duration measured at 3 months was not signific

19 The mean monthly epistaxis duration was 259.2 minutes (95% CI, 82.1-436.3

20 was significantly different from placebo for epistaxis duration.

21 condary outcomes included median duration of epistaxis during weeks 5 through 12, Epistaxis Severity

22 an presented with left nasal obstruction and epistaxis for 2 years and was diagnosed with nasopharyng

23 Drug therapy did not significantly reduce epistaxis frequency (P = .97).

24 The primary outcome was median weekly epistaxis frequency during weeks 5 through 12.

25 vs estriol vs tranexamic acid vs placebo and epistaxis frequency.

26 's thrombasthenia usually includes bruising, epistaxis, gingival hemorrhage, and menorrhagia.

27 3 months prior to inclusion corroborated by epistaxis grids completed during the same preinclusion p

28 ia based on (1) nearly a lifelong history of epistaxis, gum bleeding, petechiae, and purpura; (2) sev

29 elial growth factor monoclonal antibody) for epistaxis has been shown.

30 red colony and experienced clinical signs of epistaxis, hyphema, intramuscular hematoma, and prolonge

31 ile neutropenia, catheter-related infection, epistaxis, hypotension, nausea, and fever.

32 d embolization to management of postraumatic epistaxis in 1970.

33 ntial role for Bartonella spp. as a cause of epistaxis in dogs and potentially in other animals, incl

34 lla species was implicated in three cases of epistaxis in dogs, based upon isolation, serology, or PC

35 The North American Study of Epistaxis in HHT was a double-blind, placebo-controlled

36 adiation recall (n = 1), grade 3 hemorrhage (epistaxis) in the presence of grade 4 thrombocytopenia (

37 omen with a median of 7.0 weekly episodes of epistaxis [interquartile range {IQR}, 3.0-14.0]), 106 pa

38 Epistaxis is a major factor negatively affecting quality

39 Epistaxis is the most frequent and disabling manifestati

40 Optimal treatment for HHT-related epistaxis is uncertain.

41 dominant vascular disorder characterized by epistaxis, mucocutaneous telangiectases, and arterioveno

42 ne in the 5 g plus 2.5 g idarucizumab group (epistaxis); one receiving placebo (infusion site haemato

43 ed in treatment of spontaneous and traumatic epistaxis, palliative tumors and vascular defects, as we

44 All groups had a significant improvement in Epistaxis Severity Score at weeks 12 and 24.

45 ad experienced HHT-related epistaxis with an Epistaxis Severity Score of at least 3.0.

46 tion of epistaxis during weeks 5 through 12, Epistaxis Severity Score, level of hemoglobin, level of

47 He had a prior history of epistaxis typically lasting 5-10 minutes and consisting

48 There were five cases of mild epistaxis upon bridle insertion and four cases of superf

49 The epistaxis was treated with nasal packing, which prevente

50 Hypertension, proteinuria, and epistaxis were other potential safety concerns.

51 Mean duration of epistaxis, which was 221 minutes per month (range, 0-947

52 eria for HHT and had experienced HHT-related epistaxis with an Epistaxis Severity Score of at least 3